Entity

Time filter

Source Type

Chengde, China

Liu Y.,No. 1 Central Hospital | Yang Y.,Hebei University | Liu H.,Peking Union Medical College | Song Y.-J.,Tumor Hospital
World Chinese Journal of Digestology | Year: 2014

AIM: To investigate the effect of intraperitoneal oxaliplatin administration at different times postoperatively on colonic wound healing in rats. METHODS: Forty male Wistar rats underwent end-to-end anastomosis after colonic transection and then were randomly assigned to receive intraperitoneal administration of oxaliplatin or not as follows: group A (n = 30), 25 mg/kg oxaliplat-in; control group (n = 10). The former group was sub-divided into three equal subgroups (A1-3) and oxaliplatin was intra-abdominally injected postoperatively as follows: day 3 (A1), day 5 (A2) and day 7 (A3). Abdominal adhesion, anastomotic bursting pressure and histomorphometric parameters were assessed on the postoperative day 10. RESULTS: All the rats survived throughout the experimental period. Group A1 presented a significantly higher extent of intra-abdominal adherences than the other groups (P < 0.05). The bursting pressure was significantly lower in group A1 than in groups A2, A3 and control group (103.90 mmHg ± 7.97 mmHg vs 167.10 mmHg ± 19.84 mmHg, 178.20 mmHg ± 26.67 mmHg, 184.10 mmHg ± 23.77 mmHg; χ2 = 18.64, P = 0.0001). The submucosal thickness in groups A1, A2, A3 and control group were 82.40 μm ± 9.66 μm, 91.50 μm ± 8.74 μm, 96.00 μm ± 7.85 μm and 95.40 μm ± 8.95 μm, respectively. The myenteron thickness in groups A1, A2, A3 and control group were 487.20 μm ± 26.28 μm, 539.30 μm ± 39.46 μm, 521.00 μm ± 35.35 μm and 539.60 μm ± 45.61 μm, respectively. The alterations in submucosal thickness and myenteron thickness were most pronounced in group A1, which were significantly decreased compared to the control group and groups A2 and A3 (F = 5.05, P = 0.0051; F = 4.35, P = 0.0103). There was no significant difference regarding mucosal thickness among the groups (P = 0.0623). CONCLUSION: Intraperitoneal oxaliplatin administration is safe and feasible on postoperative day 5 after colonic resection, which may be an optimal time point for patients with colorectal carcinoma with unfavorable prognosis to accept early postoperative intraperitoneal chemotherapy. © 2014 Baishideng Publishing Group Inc. All rights reserved. Source


Shi F.,Weifang Medical College | Shi F.,PLA Fourth Military Medical University | Tan Z.,PLA Fourth Military Medical University | An H.,Weifang Medical College | And 3 more authors.
Annals of Hepatology | Year: 2016

Background. To compare the survival of Chinese cirrhotic patients with hepatocellular carcinoma (HCC) ≤ 4 cm who underwent radiofrequency ablation (RFA) alone or a combination of RFA with percutaneous ethanol injection (PEI). Material and methods. Retrospective analysis was performed for 681 cases with HCC ≤ 4 cm who were treated with RFA alone or RFA combined with PEI (RFA + PEI) between 2004 and 2011. Results. As a result, 180 patients in each group were selected after propensity score matching (PSM). Higher overall survival (OS) and recurrence-free survival (RFS) rates were achieved by RFA + PEI compared with RFA alone (P = 0.019 and 0.009, respectively). The 1-, 3-, and 5-year cumulative OS rates were 78.0, 44.4, and 30.1% for patients in RFA group and 88.2, 58.0, and 41.1% for patients in RFA + PEI group, respectively. Besides, the 1-, 3-, and 5-year cumulative RFS rates were 77.0, 43.8, and 29.2% in RFA group, and 87.9, 57.6, and 38.4% in RFA + PEI group, respectively. The local recurrence, complete ablation and five-year mortality showed no distinct differences between RFA and RFA + PEI groups in three subgroups classified with tumor size. Moreover, Cox regression multivariate analysis results showed that sex and treatment approach were significantly related to OS, whereas sex, status of HBsAg, local recurrence, and number of tumor nodule were related to RFS. Conclusion. Therefore, the combination of RFA and PEI yielded better OS and RFS rates than RFA alone for Chinese patients with HCC ≤ 4 cm. © 2016, Fundacion Clinica Medica Sur. All rights reserved. Source


Zhang L.,Sun Yat Sen University | Wang L.-Y.,Sun Yat Sen University | Deng Y.-M.,Tumor Hospital | Wang F.-H.,Sun Yat Sen University | And 6 more authors.
Journal of B.U.ON. | Year: 2011

Purpose: Small bowel adenocarcinoma (SBA) is a rare malignancy, and most patients present with unresectable or metastatic disease. Thus far, no standard chemotherapeutic regimen has been established and related data are scarce, especially in Eastern countries. The purpose of this multicenter study was to evaluate the efficacy and toxicity of oxaliplatin combined with fluoropyrimidines in Chinese patients with advanced SBA. Methods: Advanced SBA patients who received FOLFOX (5-fluorouracil/5-FU plus leucovorin and oxaliplatin)/CAPOX (capecitabine plus oxaliplatin) as first-line chemotherapy between February, 2004 and October, 2010 were identified from 3 large medical centers in China. The response rate (RR), progression-free survival (PFS), overall survival (OS), and chemotherapy-associated toxicity were evaluated. Cox models were applied for multivariate analyses. Results: Of 34 patients, with SBA 28 received FOLFOX and 6 CAPOX. The objective response (OR) and disease control (DC) rates were 32.3% and 61.7%, respectively. The median PFS and OS were 6.3 and 14.2 months, respectively. The toxicity was tolerable, grade 3-4 toxicity was rare. In multivariate analysis, only multi-organ metastasis reached borderline significance for shorter PFS (p=0.059), but the variables of age (>65 years; p=0.001), and multi-organ metastasis (p=0.001) were significantly associated with poor OS. Conclusion: To our knowledge, this multicenter retrospective study is the first and largest one among Asian studies at present estimating oxaliplatin combined with fluoropyrimidines as first-line chemotherapy for advanced SBA. FOLFOX/CAPOX is proved effective for advanced SBA in this study, but the results do not absolutely agree with previous studies from Western countries, showing that further studies are still needed. © 2011 Zerbinis Medical Publications. Source


Wang L.,Sun Yat Sen University | Zhang L.,Sun Yat Sen University | Deng Y.,Tumor Hospital | Wang F.,Sun Yat Sen University | And 8 more authors.
Chinese Journal of Clinical Oncology | Year: 2012

Objective: This study evaluates the efficacy and toxicity of oxaliplatin regimen combined with fluoropyrimidines in Chinese patients with advanced small bowel adenocarcinoma (SBA). Methods: Advanced SBA patients who received FOLFOX/CAPOX as the first-line chemotherapy between April 2004 and October 2010 from three hospitals were retrospectively analyzed. The response rate, progression-free survival, overall survival, and chemotherapy-associated toxicity were evaluated using SPSS 13.0. Results: A total of 34 patients were enrolled in the study, 28 of which received FOLFOX6 and 6 received XELOX. The objective response and disease control rates were 32.3% and 61.7%, respectively. The median progression-free survival and overall survival were 6.3 and 14.2 months, respectively. The toxicity was tolerable, and a toxicity grade of 3-4 was rare. In addition, anorexia (58.8%), nausea (47.1%), and peripheral neuropathy (32.4%) were the most common toxic reactions, with a toxicity grade of 1-2. Conclusions: This study was the first to report the efficacy of oxaliplatin combined with fluoropyrimidines as the first-line chemotherapy for advanced SBA in China. FOLFOX/CAPOX is proven effective and safe for advanced SBA, and is worthy of further study. Source


Liu C.,Shandong University | Qin Z.P.,Tumor Hospital | Fan Z.N.,Shandong University | Zhao W.J.,Shandong University | And 4 more authors.
Medical Hypotheses | Year: 2012

Epulis is a relapsable lesion in gingiva without specific treatment for its unexplained pathogenesis. Nowadays, surgical excision is the most popular method of treatment. To prevent recurrence, it is necessary to resect diseased tissues thoroughly, and even to remove the involved teeth. However, this may cause functional and cosmetic deformities. Therefore, it is urgent to find a new therapy without severe side effects. Infantile hemangioma is a common benign pediatric tumor which shares many features with epulis, such as rich vascularity, high incidence of female patients, high hormone level and similar treatments. A recent study showed that propranolol, a beta adrenergic receptor (β-AR) antagonist, was effective as treatment for infantile hemangioma. Our preliminary work showed that mRNA and protein levels of β2-AR were higher in epulis than in adjacent tissue. Therefore, we hypothesize that intralesional injection of propranolol may be useful as epulis treatment. Further work need to be done to confirm the safety and therapeutic effect of the treatment. After that, this specific β2-AR antagonist may be the first choice for epulis treatment. © 2011 Elsevier Ltd. Source

Discover hidden collaborations